期刊文献+

自拟调脂消斑方治疗动脉粥样硬化的临床观察 被引量:2

Clinical Observation on Self-made Tiaozhi Xiaoban Prescription in the Treatment of Atherosclerosis
下载PDF
导出
摘要 目的观察中药调脂消斑方联合他汀类药物治疗动脉粥样硬化的临床疗效。方法选取62例痰瘀阻络型颈动脉粥样硬化患者,随机分为治疗组36例(中药联合阿托伐他汀钙),对照组26例(阿托伐他汀钙)。比较治疗前、后血脂水平,颈部动脉内膜厚度、斑块厚度、狭窄率水平,观察心脑血管不良事件的发生。结果完成随访60例,2例对照组患者因肝功异常退出。治疗组及对照组患者TC、LDL水平较前下降(P<0.05)。治疗组患者颈部动脉内膜厚度、斑块厚度及狭窄程度均较治疗前下降(P<0.05)。治疗组,无严重心脑不良事件发生。结论中药调脂消斑方联合他汀药物能有效降低患者血脂水平,改善患者颈部血管粥样硬化程度,且耐受性佳。 Objective To observe the clinical effect of Chinese medicine Tiaozhi Xiaoban prescription associated with the statin drugs in treating atherosclerosis. Method Selecting 62 patients with carotid artery atherosclerosis, they were randomly divided into treatment group of 36 cases (Chinese medicine associated with Atorvastatin calcium) and control group of 26 cases (Atorvastatin calcium). The level of the blood lipid, the thickness of carotid artery intima, the thickness of carotid artery patch, and the Stenosis rate before and after the treatment were compared. The adverse events about the cardiovascular accident or cerebral vascular accident was observed. Results 60 patients were followed-up. 2 cases in the control group withdraw because of the abnormal liver function. The levels of the TC and LDL were decreased in the treatment group and control group (P 〈 0. 05 ). The thickness of carotid artery intima, the thickness of carotid artery patch and the Stenosis rate were decreased in the treatment group (P 〈 0.05 ). There were no serious adverse events. Conclusion The level of the blood lipid could be effectively reduced, the degree of carotid atherosclerosis could be improved, and the tolerance is well by using the Chinese medicine Tiaoxhi Xiaoban prescription associated with the statin drugs.
出处 《光明中医》 2016年第14期2050-2052,共3页 GUANGMING JOURNAL OF CHINESE MEDICINE
关键词 颈动脉粥样硬化 阿托伐他汀钙 中医药疗法 Carotid atherosclerosis Atorvastatin calcium Therapy of traditional Chinese medicine
  • 相关文献

参考文献5

  • 1Reiner Z,Catapano AL,De Backer G,et al.For ESC Committee for Practice Guidelines ( CPG )2008-2010 and 2010-2012 Committees.ESC/EAS Guidelines for the management of dyslipidaemias:the Task Force for the management of dyslipidaemias of the European Society of Cardiology ( ESC ) and the European Atherosclerosis Society ( EAS )[J].Eur Heart J,2011,32(14):1769-1818.
  • 2中华医学会神经病学分会脑血管病学组缺血性脑卒中二级预防指南撰写组.中国缺血性卒中和短暂性脑缺血发作二级预防指南2010[S].中华神经科杂志,2010,43(2):154-160.
  • 3张瑞淑,张遥,闫荟,刘爽,许宁,李阳.他汀类药物的不良反应研究进展[J].中国循证心血管医学杂志,2013,5(5):547-549. 被引量:16
  • 4孟晓萍,王素香,张基昌,李震霄,耿丽,殷春媛.普罗布考联合降脂药物对动脉粥样硬化病人的干预治疗[J].中华医学杂志,2009,89(28):1986-1988. 被引量:37
  • 5赵步长,伍海勤,王一民,宋琳琳.动脉粥样硬化中医浅析[J].光明中医,2012,27(12):2518-2522. 被引量:30

二级参考文献41

共引文献80

同被引文献60

引证文献2

二级引证文献21

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部